BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34030133)

  • 21. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.
    Chen X; Wang X; Ruan A; Han W; Zhao Y; Lu X; Xiao P; Shi H; Wang R; Chen L; Chen S; Du Q; Yang H; Zhang X
    Clin Cancer Res; 2014 May; 20(10):2617-30. PubMed ID: 24647573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OTUD1 stabilizes PTEN to inhibit the PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize ccRCC to TKIs.
    Liu W; Yan B; Yu H; Ren J; Peng M; Zhu L; Wang Y; Jin X; Yi L
    Int J Biol Sci; 2022; 18(4):1401-1414. PubMed ID: 35280681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HOXA6 inhibits cell proliferation and induces apoptosis by suppressing the PI3K/Akt signaling pathway in clear cell renal cell carcinoma.
    Wu F; Wu S; Tong H; He W; Gou X
    Int J Oncol; 2019 Jun; 54(6):2095-2105. PubMed ID: 31081053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
    Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
    Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FABP5 regulates the proliferation of clear cell renal cell carcinoma cells via the PI3K/AKT signaling pathway.
    Lv Q; Wang G; Zhang Y; Han X; Li H; Le W; Zhang M; Ma C; Wang P; Ding Q
    Int J Oncol; 2019 Apr; 54(4):1221-1232. PubMed ID: 30968158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.
    Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
    Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
    Long Q; Sun J; Lv J; Liang Y; Li H; Li X
    Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.
    Lin YC; Lu LT; Chen HY; Duan X; Lin X; Feng XH; Tang MJ; Chen RH
    Cancer Res; 2014 Dec; 74(23):6935-46. PubMed ID: 25293974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exosomal microRNA-15a from ACHN cells aggravates clear cell renal cell carcinoma via the BTG2/PI3K/AKT axis.
    Li DY; Lin FF; Li GP; Zeng FC
    Kaohsiung J Med Sci; 2021 Nov; 37(11):973-982. PubMed ID: 34337864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma.
    Augello G; Emma MR; Azzolina A; Puleio R; Condorelli L; Cusimano A; Giannitrapani L; McCubrey JA; Iovanna JL; Cervello M
    Cancer Lett; 2021 Oct; 519():250-262. PubMed ID: 34314755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
    Qiu X; Gu Y; Ni Y; Li Q
    Biomed Res Int; 2020; 2020():2064582. PubMed ID: 33178820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.
    Wang Q; Ding H; He Y; Li X; Cheng Y; Xu Q; Yang Y; Liao G; Meng X; Huang C; Li J
    Cancer Lett; 2019 Mar; 444():9-19. PubMed ID: 30543814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression.
    Ma Q; Peng Z; Wang L; Li Y; Wang K; Zheng J; Liang Z; Liu T
    Int J Oncol; 2016 Dec; 49(6):2589-2599. PubMed ID: 27779660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.
    White NM; Masui O; Newsted D; Scorilas A; Romaschin AD; Bjarnason GA; Siu KW; Yousef GM
    Br J Cancer; 2014 Mar; 110(5):1250-9. PubMed ID: 24496460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.
    Li JK; Chen C; Liu JY; Shi JZ; Liu SP; Liu B; Wu DS; Fang ZY; Bao Y; Jiang MM; Yuan JH; Qu L; Wang LH
    Mol Cancer; 2017 Jun; 16(1):111. PubMed ID: 28659173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.
    Gao X; Jiang P; Zhang Q; Liu Q; Jiang S; Liu L; Guo M; Cheng Q; Zheng J; Yao H
    J Exp Clin Cancer Res; 2019 Aug; 38(1):362. PubMed ID: 31426831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.
    Liu W; Chen H; Wong N; Haynes W; Baker CM; Wang X
    Cancer Lett; 2017 May; 394():65-75. PubMed ID: 28257806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NUPR1 participates in YAP-mediate gastric cancer malignancy and drug resistance via AKT and p21 activation.
    Jiang L; Wang W; Li Z; Zhao Y; Qin Z
    J Pharm Pharmacol; 2021 Apr; 73(6):740-748. PubMed ID: 33793788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.